Maxbrim Eye Drop is a combination ophthalmic solution containing Brinzolamide 1% w/v and Brimonidine 0.2% w/v, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brinzolamide is a carbonic anhydrase inhibitor that decreases aqueous humor production by inhibiting the enzyme carbonic anhydrase in the ciliary processes, thereby reducing IOP. Brimonidine is an alpha-2 adrenergic receptor agonist that lowers IOP through dual mechanisms: decreasing aqueous humor production and increasing uveoscleral outflow. The synergistic effect of these agents provides effective IOP control, which is critical in preventing optic nerve damage and visual field loss associated with glaucoma. Maxbrim Eye Drop is typically administered as one drop in the affected eye(s) two to three times daily, as directed by a healthcare professional. Caution is advised in patients with hypersensitivity to any component, severe cardiovascular disease, or hepatic impairment. Common adverse effects include ocular discomfort, blurred vision, and dry mouth. Patients should avoid contact lens use during administration and consult their ophthalmologist for appropriate monitoring. Maxbrim Eye Drop offers a convenient and efficacious option for managing elevated IOP in glaucoma therapy.